Bleeding After Menopause: Why Any Spotting Needs Evaluation

The short answer

Here is the honest framing. Most postmenopausal bleeding turns out to be benign, and the single most common explanation is thinning, fragile vaginal and vulvar tissue from estrogen loss — what clinicians now call genitourinary syndrome of menopause. But endometrial cancer announces itself through bleeding in the great majority of cases, and it is one of the few gynecologic cancers with an early, obvious warning sign. Evaluating every episode is how that warning sign stays useful. A single pink smear on toilet paper, a brown streak in discharge, one episode that stops on its own — all of it counts.

If you are on hormone therapy, the rules are different but not looser. Some bleeding patterns are expected on certain regimens and some are not, and the distinction is specific enough to be worth knowing before you call your clinician. This page covers what counts as postmenopausal bleeding, the full list of causes from most to least common, exactly what an evaluation involves — transvaginal ultrasound, the endometrial thickness threshold, when a biopsy is added — and how bleeding on hormone therapy is judged differently.

What actually counts as postmenopausal bleeding

Menopause is a retrospective diagnosis: you are postmenopausal once you have gone 12 consecutive months without a menstrual period, as ACOG describes in its patient guidance on the menopause years. Bleeding during the transition itself — irregular, heavier, lighter, skipped, closer together — is a different clinical situation with a different threshold for concern. The clock only starts at that 12-month mark.

Once you are past it, the definition of abnormal is deliberately broad. It includes a full bleed that looks like a period returning. It includes a single spot of red blood on toilet tissue. It includes pink-tinged discharge, rust or brown streaking, blood noticed only after sex, and blood noticed only once and never again. There is no volume floor and no duration floor. A one-time episode that resolves by itself still meets the definition, because the endometrial changes that cause bleeding are frequently intermittent — an episode that stops on its own tells you nothing reassuring about its source.

What does not count is blood that is not coming from the vagina. Blood on the tissue can originate in the urethra or bladder, from hemorrhoids or an anal fissure, or from a skin fissure on the vulva. These are worth mentioning to your clinician rather than self-sorting, because the physical exam distinguishes them in seconds and misattributing uterine bleeding to hemorrhoids is a common way months get lost.

One more category: if you have had a hysterectomy, bleeding is still abnormal and still needs a look. The source may be the vaginal cuff, the cervix if it was preserved, or atrophic tissue — but it is not something to dismiss on the grounds that there is no uterus left to bleed.

Why "wait and see" is the wrong instinct here

Most symptoms of menopause reward patience. Hot flashes fluctuate, sleep improves and worsens, mood shifts week to week, and reasonable clinicians often suggest watching a symptom for a while before acting. Postmenopausal bleeding is the exception, and the reason is structural rather than statistical.

Endometrial cancer is unusual among gynecologic cancers in that it produces a visible symptom early — bleeding — before it spreads. There is no population screening test for it. Ultrasound is not recommended as a screening tool for women without symptoms. That means bleeding is doing the job that a screening program would otherwise do, and the value of that signal depends entirely on it being acted on rather than absorbed.

The arithmetic favors you here. The large majority of postmenopausal bleeding turns out to have a benign explanation, so the realistic outcome of an evaluation is reassurance plus, often, a treatable diagnosis like atrophy or a polyp that was making you uncomfortable anyway. The evaluation itself is not arduous: an office visit, a pelvic exam, an ultrasound, and in some cases a brief in-office biopsy. Weighed against the cost of a delayed cancer diagnosis, the asymmetry is stark.

The particular trap is the episode that stops. Someone spots once, time passes with nothing further, and the episode gets filed away as a fluke — so when bleeding returns, the same reasoning gets applied a second time. Intermittency is characteristic of the conditions being ruled out, not evidence against them.

The causes, from most common to most important to exclude

Benign causes substantially outnumber malignant ones, but the list is worth knowing in order, because it explains why the evaluation is structured the way it is: the tests are aimed at the uterine lining first, even when the likeliest source is the vaginal wall.

Atrophic changes lead the list. Endometrial and vaginal atrophy both produce thin, fragile, easily disrupted tissue. Polyps — endometrial or cervical — are the next common finding and are often the explanation for repeated small bleeds with no other symptoms. Endometrial hyperplasia sits in a middle category: it is not cancer, but certain subtypes carry meaningful progression risk and are treated precisely to prevent that. Hormone therapy accounts for a substantial share of bleeding in women taking it, discussed separately below. Less commonly, infection, cervical or vaginal lesions, trauma, anticoagulant medication, or fibroids contribute.

Endometrial cancer sits at the bottom of the frequency list and the top of the priority list. That inversion is the whole logic of the workup.

Vaginal atrophy and GSM: the most likely answer, but not an assumption

Genitourinary syndrome of menopause is the current umbrella term for what used to be split into vaginal atrophy and urogenital symptoms. The 2020 NAMS position statement on GSM describes a cluster that includes vaginal dryness, burning, irritation, painful intercourse, urinary urgency, frequency, and recurrent urinary tract infections. The tissue changes underneath — thinning epithelium, reduced blood flow, loss of elasticity, shifted vaginal pH — are what make the surface fragile enough to bleed with minimal friction.

Two features of GSM matter for anyone reading this page. First, NAMS emphasizes that unlike hot flashes, GSM does not improve on its own with time; without treatment it typically progresses. Second, it is genuinely common in postmenopausal women, which is exactly why it is tempting to assume it is the answer — and why that assumption is unsafe. Atrophy and endometrial pathology can coexist in the same person. A pale, thin, obviously atrophic vagina on exam does not tell you what the endometrium looks like.

So GSM belongs in the differential from the start, and treating it is often part of the plan, but it does not substitute for evaluating the uterine lining. The correct sequence is: evaluate the bleeding, and treat the atrophy alongside or after — not instead.

On treatment, the NAMS GSM statement supports low-dose vaginal estrogen as effective for moderate to severe symptoms, with minimal systemic absorption at the doses used, alongside non-hormonal moisturizers and lubricants. Whether that is appropriate for you is a conversation with a clinician who knows your history.

What the evaluation actually involves

An evaluation for postmenopausal bleeding is usually a single visit with a small number of steps, most of which happen in the office. Knowing the sequence in advance removes most of the anxiety, because the process is far less invasive than people imagine.

It begins with history: when the bleeding started, how much, whether it followed intercourse, what medications you take (including hormone therapy, tamoxifen, and anticoagulants), and your risk factors. Then a pelvic and speculum exam, which identifies visible vaginal, vulvar, and cervical sources and assesses tissue quality — this is where atrophy, a cervical polyp, or a lesion becomes obvious.

Then imaging or sampling. ACOG's committee opinion on the role of transvaginal ultrasonography describes transvaginal ultrasound as a reasonable first-line approach in women with postmenopausal bleeding, with endometrial biopsy as the alternative first step. Either order is defensible; what is not defensible is stopping before one of them has answered the question.

An endometrial biopsy is done in the office with a thin flexible catheter passed through the cervix. It is brief, usually causes cramping similar to a strong menstrual cramp, and does not require anesthesia. Ask your office whether they recommend taking an over-the-counter pain reliever beforehand. Results are usually available within days rather than weeks.

The 4 mm endometrial thickness threshold, explained

The number most people encounter after an ultrasound is the endometrial thickness, or endometrial stripe. ACOG's committee opinion on transvaginal ultrasonography states that in a postmenopausal woman with bleeding, an endometrial thickness of 4 mm or less carries a very high negative predictive value for endometrial cancer, and that in that setting endometrial sampling is not required as the initial step. A measurement greater than 4 mm does not mean cancer — it means ultrasound alone cannot settle the question, so tissue is needed.

Two conditions have to be met for that threshold to be usable. The image must be adequate, and the stripe must be measurable. ACOG notes that if the endometrium cannot be adequately visualized — because of fibroids, adenomyosis, prior surgery, body habitus, or uterine position — a thin measurement cannot be inferred, and an alternative evaluation is required rather than assumed reassurance. "The endometrium was not well seen" is not a normal result.

The threshold also does not survive recurrence. ACOG is clear that persistent or recurrent postmenopausal bleeding warrants further evaluation regardless of endometrial thickness. If you bled, had a thin stripe, and then bled again months later, that second episode is a new clinical event, not a repeat of one already answered.

Finally, the 4 mm figure applies specifically to women who are bleeding. It is not a screening cutoff, and it is not the number used to interpret an incidental finding in someone with no symptoms — a distinction covered below.

When ultrasound is not enough

A blind endometrial biopsy samples tissue from across the cavity, which works well for diffuse processes such as hyperplasia or atrophy. It is less reliable for focal lesions: a polyp or a localized cancer occupying a small area of the cavity can be missed by a catheter that happened not to pass over it. This is the main reason a normal biopsy does not end the conversation when bleeding continues.

Saline infusion sonography addresses this by instilling a small amount of sterile saline into the cavity during ultrasound, separating the walls and outlining focal lesions that a standard scan flattens into a thickened stripe. Hysteroscopy goes further by putting a camera into the cavity, allowing lesions to be seen and sampled or removed directly.

Certain situations move a woman toward these tests earlier. Tamoxifen, used in breast cancer treatment, produces endometrial changes that make ultrasound thickness measurements unreliable, so direct evaluation of the cavity is generally preferred over relying on a stripe measurement. Cervical stenosis can make an office biopsy technically impossible. A biopsy returning "insufficient tissue for diagnosis" is not a negative result — it is a non-result, and it needs to be followed up rather than filed.

The practical takeaway: if your bleeding continues after a reassuring workup, the correct response is escalation to a test that can see the cavity, not repetition of the test that already came back thin.

Bleeding while on hormone therapy: different expectations, same red lines

Hormone therapy changes what is expected but not what is investigated. The NAMS 2022 hormone therapy position statement establishes the foundational rule: a woman with an intact uterus who takes systemic estrogen requires adequate progestogen, because unopposed estrogen increases the risk of endometrial hyperplasia and cancer. Bleeding on hormone therapy is therefore always read against the question of whether the endometrium is adequately protected.

Expectations depend on the regimen. On cyclic or sequential therapy, where progestogen is given for part of each cycle, predictable withdrawal bleeding at the end of the progestogen phase is designed into the regimen and is not abnormal. On continuous combined therapy, where estrogen and progestogen are taken daily, the goal is no bleeding — but irregular spotting during the early months is common as the endometrium adjusts, and it typically diminishes over time.

What is not expected: bleeding that begins after a stable, bleed-free stretch; bleeding that is heavy; unscheduled bleeding on a cyclic regimen that occurs outside the expected window; and spotting on a continuous combined regimen that persists well beyond the early adjustment period or worsens rather than settling. Any of these should be evaluated with the same tools used in a woman not on therapy.

Two practical contributors are worth checking first because they are fixable: missed or irregular dosing, which is a frequent cause of breakthrough bleeding, and recent dose or formulation changes. Neither one substitutes for evaluation if bleeding persists.

Bleeding while using vaginal estrogen

Low-dose vaginal estrogen is used for genitourinary symptoms rather than systemic ones, and the NAMS GSM position statement describes it as effective for moderate to severe GSM with minimal systemic absorption at standard doses. That low absorption is precisely why bleeding on vaginal estrogen should not be waved off as a hormone side effect.

Some women notice light spotting in the first weeks of vaginal estrogen use as fragile atrophic tissue is handled by an applicator or begins to remodel. That mechanism is plausible, and it is often what is going on. But it is also indistinguishable, from the outside, from bleeding with an entirely different source. The correct response is to report it, be examined, and let the evaluation — not the timing — determine the explanation.

The same principle applies to the temptation to start vaginal estrogen as a therapeutic test: "if the spotting stops on treatment, it must have been atrophy." That reasoning fails because bleeding from other sources is frequently intermittent and can appear to respond to anything started while it happens to be quiet. Treat the atrophy, but evaluate the bleeding on its own track.

If you have a history of breast cancer or another estrogen-sensitive condition, the decision about vaginal estrogen involves your oncology team as well, and non-hormonal moisturizers and lubricants are part of that discussion.

Thickened endometrium found with no bleeding at all

A different scenario reaches many women: an ultrasound done for an unrelated reason — pelvic pain, an ovarian cyst, a fibroid check — reports a thickened endometrium in someone who has never had a drop of postmenopausal bleeding. This is a genuinely distinct clinical problem, and applying the bleeding thresholds to it leads to unnecessary procedures.

The Society of Obstetricians and Gynaecologists of Canada published a 2024 guideline addressing exactly this: asymptomatic endometrial thickening in postmenopausal women. The core message is that an incidental finding in the absence of bleeding carries a much lower risk of malignancy than the same measurement in a woman who is bleeding, and that it does not automatically require biopsy. Management is individualized, weighing the appearance of the endometrium and the woman's own risk profile rather than applying the symptomatic cutoff.

This is also why transvaginal ultrasound is not used as a screening test for endometrial cancer in the general postmenopausal population. Screening asymptomatic women would generate a large volume of findings that require invasive follow-up while identifying very little disease.

If you are in this situation, the useful question for your clinician is not whether your particular measurement is dangerous in isolation, but: given that I have no bleeding, what is your reasoning for observing versus sampling in my case? And the standing instruction is unchanged: if bleeding ever starts, that changes the category immediately and the evaluation proceeds.

Risk factors that raise the stakes

Every woman with postmenopausal bleeding gets evaluated, so risk factors do not change whether to act. What they change is the urgency, the likelihood that a clinician moves directly to tissue sampling, and how aggressively a normal result is questioned if bleeding continues.

The dominant theme among endometrial cancer risk factors is prolonged estrogen exposure without adequate progestogen opposition. That includes obesity, since adipose tissue converts androgens to estrogen and provides ongoing endometrial stimulation after the ovaries stop. It includes a history of unopposed systemic estrogen use with an intact uterus, the exposure the NAMS 2022 statement exists to prevent. It includes polycystic ovary syndrome and chronic anovulation earlier in life, late menopause, and never having been pregnant.

Other factors sit alongside: type 2 diabetes, tamoxifen use, a prior diagnosis of endometrial hyperplasia, and a family history suggesting Lynch syndrome — particularly a pattern of colorectal, endometrial, or ovarian cancers across relatives, which warrants a genetics conversation independent of the current bleeding episode.

Being at low risk does not make bleeding safe to ignore. Plenty of endometrial cancers occur in women with no identified risk factor, which is another reason the evaluation threshold is set at any bleeding rather than any bleeding plus risk.

What to do this week if you are bleeding

Call and describe the symptom precisely. The phrase that gets the right appointment is "I am postmenopausal and I have had vaginal bleeding" — not "I think my period came back" and not "a little spotting." Ask for an appointment that includes a pelvic exam, and ask whether an ultrasound can be arranged at or near the same visit so you are not waiting through two separate scheduling cycles.

Before the visit, write down four things: the date bleeding started and every date it recurred, how heavy it was in terms you can describe (a spot on tissue, a panty liner, a pad), whether it followed intercourse or an exam, and a complete medication list including hormone therapy, vaginal estrogen, tamoxifen, blood thinners, and supplements. Note any accompanying symptoms — pelvic pain, discharge, unintended weight loss, urinary changes.

Do not stop prescribed hormone therapy on your own before the appointment. Stopping alters the bleeding pattern and removes information your clinician needs to interpret what is happening; it can also trigger a withdrawal bleed that muddies the picture further.

And keep the appointment even if the bleeding has stopped by then. Resolution before the visit is the single most common reason evaluations get cancelled, and it is the least informative reason to cancel one.

If your first evaluation was normal and bleeding continues

A thin endometrial stripe or a benign biopsy answers the question for the episode that prompted it. It does not immunize you against the next one. ACOG advises that persistent or recurrent postmenopausal bleeding requires further evaluation regardless of the earlier endometrial thickness, and the reason is mechanical rather than statistical: blind sampling and a single ultrasound plane can both miss a focal lesion.

So the escalation path after a normal first workup with continued bleeding generally moves toward direct visualization — saline infusion sonography to outline the cavity, or hysteroscopy with directed biopsy to see and sample it. If your original biopsy returned insufficient tissue, that result should be treated as unfinished business rather than as a benign finding.

Meanwhile, the benign diagnoses deserve actual treatment rather than acknowledgment. If atrophy is contributing, the NAMS GSM statement supports treating it, and treated tissue bleeds less — which both improves symptoms and makes future bleeding episodes more informative. If a polyp was found, removing it usually resolves the bleeding and provides tissue for examination at the same time.

The reasonable script for a follow-up appointment: "I have bled again since my normal ultrasound. What test can see inside the cavity, and can we schedule it now rather than waiting for another episode?"

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• I am postmenopausal and I have had vaginal bleeding — can we do a pelvic exam and arrange a transvaginal ultrasound at or close to this visit?
• What was my endometrial thickness measurement, and was the endometrium adequately visualized or was any part of it unmeasurable?
• Given my result, are you recommending an endometrial biopsy now, and what would change your mind either way?
• If my biopsy comes back as insufficient tissue, what is the plan — will we repeat it or move to hysteroscopy?
• I have bled again since my normal ultrasound. What test can actually see inside the uterine cavity, and can we schedule it now?
• I am on hormone therapy — is the bleeding I am having expected for my specific regimen, and should I keep taking it exactly as prescribed until we know more?
• If atrophy is contributing, what treatment do you recommend for that alongside the evaluation, rather than instead of it?

Frequently asked questions

Is one spot of blood after menopause really worth a doctor's visit?

Yes. ACOG's guidance sets the threshold at any bleeding after menopause, with no minimum volume or duration. The conditions being ruled out frequently bleed intermittently and lightly, so a single spot that never recurs carries the same evaluation recommendation as a heavier bleed. The workup is typically one office visit with an exam and an ultrasound.

Can my period actually come back after a year without one?

No. Once you have completed 12 consecutive months without a period, ovarian function has stopped and a true menstrual period does not resume. Bleeding after that point has some other source — most often atrophic tissue, a polyp, or hormone therapy — and calling it a returned period is the most common reason evaluation gets delayed.

What does an endometrial thickness of 4 mm or less mean?

In a postmenopausal woman who is bleeding, ACOG's committee opinion on transvaginal ultrasonography describes an endometrial thickness of 4 mm or less as having a very high negative predictive value for endometrial cancer, so initial endometrial sampling is not required. Two caveats: the measurement only counts if the endometrium was adequately visualized, and it does not apply if bleeding recurs, which triggers further evaluation regardless.

Does an endometrial biopsy hurt?

It typically causes cramping comparable to a strong menstrual cramp while the sample is taken, sometimes with lighter cramping afterward. It is done in the office without anesthesia through a thin flexible catheter. It is reasonable to ask your office in advance whether they recommend an over-the-counter pain reliever beforehand and what else they offer for pain management.

I am on continuous combined hormone therapy and spotting. Is that normal?

Unscheduled spotting is common in the early months of continuous combined estrogen-progestogen therapy and generally decreases over time as the endometrium adjusts. What is not expected is spotting that persists well beyond that early adjustment period, gets heavier, or restarts after a stable bleed-free stretch. Those patterns should be evaluated the same way bleeding in a woman not on therapy would be. Do not stop your therapy on your own before the appointment.

Can vaginal dryness alone cause bleeding?

Yes. Genitourinary syndrome of menopause thins the vaginal epithelium and reduces elasticity, and the NAMS 2020 position statement notes it progresses without treatment. That fragile tissue bleeds readily with intercourse, an exam, or friction. It is the most common explanation for postmenopausal spotting — but it can coexist with endometrial disease, so it is a diagnosis confirmed by evaluation rather than assumed from symptoms.

My ultrasound found a thickened endometrium but I have never bled. Do I need a biopsy?

Not automatically. The Society of Obstetricians and Gynaecologists of Canada's 2024 guideline on asymptomatic endometrial thickening treats this as a separate situation from bleeding, with a substantially lower risk of malignancy and management individualized to the appearance of the endometrium and your risk factors rather than applied from the symptomatic threshold. If bleeding ever begins, that changes the category and evaluation should proceed.

I had a hysterectomy. Does bleeding still matter?

Yes. Bleeding after hysterectomy can come from the vaginal cuff, from a preserved cervix, or from atrophic vaginal tissue, and it should be examined rather than dismissed on the assumption that there is nothing left to bleed. Tell whoever you call that you have had a hysterectomy, and specify whether the cervix was removed if you know.

How quickly do I need to be seen?

Promptly — this is not a symptom to watch and wait on. Call as soon as you notice bleeding and ask for the soonest available appointment that includes a pelvic exam. Go to urgent or emergency care instead if the bleeding is heavy or comes with severe pain, dizziness, or fainting. For lighter bleeding, ask that the exam and ultrasound be arranged together so you are not waiting through two rounds of scheduling.

Should I stop my hormone therapy because I am bleeding?

Not on your own. Stopping abruptly can produce a withdrawal bleed that obscures the pattern your clinician needs to interpret, and it removes information about how your current regimen is behaving. Report the bleeding, keep taking your prescribed therapy as directed, and let your clinician decide whether a regimen change is part of the plan. Do mention any missed doses, since irregular dosing is a common cause of breakthrough bleeding.

Primary sources

1. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ)
2. ACOG Committee Opinion: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding
3. Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women. J Obstet Gynaecol Can, 2024. PMID 38901794.
4. The 2020 genitourinary syndrome of menopause position statement of NAMS. Menopause, 2020. PMID 32852449.
5. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
6. ACOG: The Menopause Years (patient FAQ)